November 9, 2023 11:09 AM ESTUpdated November 10, 03:48 PM
News Briefing

In­tel­lia plans to file IND for AATD tri­al next year; As­cid­i­an rais­es $40M

Jaimy Lee

Deputy Editor

Lei Lei Wu

News Reporter

In­tel­lia aims to start AATD tri­al next year: The gene edit­ing com­pa­ny an­nounced Thurs­day that it plans to file an ap­pli­ca­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Boehringer’s up­dat­ed re­sults in HER2-mu­tat­ed lung can­cer im­press

Schol­ar Rock names new CEO, adds biotech vet­er­ans in C-suite re­build

Mer­ck KGaA to buy rare can­cer biotech Spring­Works for $3.9B

Bio­haven gets an up to $600M in­vest­ment; Prile­nia, Fer­rer make a deal in Eu­rope

Rev­o­lu­tion Med­i­ci­nes' KRAS drug shows po­ten­tial in ear­ly cut of lung can­cer da­ta

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times